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Autoimmunity is often familial, suggesting that inborn genetic variations might underlie its development.
Curiously, autoimmunity has long been thought to be typically polygenic. Contrary to this prediction and
consistent with growing discoveries of monogenic autoimmunity, Oftedal et al. discovered heterozygous
dominant-negative AIRE mutations in patients with certain forms of autoimmunity.The genetic basis of autoimmunity is a
complex problem that awaits a simple so-
lution. More-complex problems, such as
gravity and life, were explained, respec-
tively, with a single equation and a double
helix. When the proposed solution to a
problem is more complicated than the
problem itself, there is often something
wrong. This is neatly illustrated with
the results obtained by the traditional
approach in complex genetics, best
exemplified by genome-wide association
studies (GWASs). Many polymorphisms
were proposed to be weakly associated
with a variety of autoimmune diseases.
In reviewing these data, missing intelligi-
bility is a greater problem than missing
heritability. The assumption behind these
large population-based genetic studies
has been the idea that there is both
phenotypic and genetic homogeneity.
Autoimmune diseases were claimed to
exist as a few distinctive entities and pa-
tients with each condition were thought
to share a genetic predisposition. Under-
standably, on such premises, most if not
all GWASs failed to reveal novel mecha-
nisms that would illuminate pathogenesis
and to provide causal relationships that
would benefit patients. This failure is
also explained, for maladies that affect
patients in reproductive age, by the
assumption that there would be no fitness
cost and common variants could be
causal. By contrast, patient-based ge-
netic studies, including studies of single
patients, have been very successful
(Casanova et al., 2014; Cheng and Ander-
son, 2012). Mendelian forms of autoim-986 Immunity 42, June 16, 2015 ª2015 Elsevmunity have been incredibly instructive
in how immune tolerance is maintained
and how autoimmunity develops. Count-
less patients have benefited from these
advances.
Autoimmune polyglandular syndrome
type 1 (APS1 [MIM: 240300]) is a Mende-
lian disorder characterized by multiple or-
gan-specific autoimmune diseases. The
most prevalent clinical features include
two autoimmune endocrine conditions,
adrenal insufficiency and hypoparathy-
roidism, as well as a chronic infectious
disease, mucocutaneous candidiasis
(Cheng and Anderson, 2012). The latter
disease is also autoimmune; APS1 sub-
jects develop autoantibodies to IL-17A
and IL-17F, two cytokines that play
a critical role in protective immunity
against Candida. Affected individuals
also develop many other autoimmune
problems, such as vitiligo and pernicious
anemia, which vary between individuals.
From a genetic perspective, the disease
is typically inherited in an autosomal-
recessive (AR) fashion and the defective
gene, AIRE (encoding AIRE, for autoim-
mune regulator), was first identified in hu-
mans through a superb positional cloning
effort in the late 1990s. Some mutations
were nonsense and frameshift, suggest-
ing that they were loss of function. The
identification of AIRE opened up a new
rich area of biology where we have now
come to appreciate that AIRE operates
as a critical transcriptional regulator to
promote the broad display of tissue-spe-
cific antigens in the thymus for the induc-
tion of tolerance (Anderson et al., 2002).ier Inc.Given that AIRE is such a key regulator
of tolerance, could heterozygous AIRE
mutations underlie autosomal-dominant
(AD) autoimmunity, by haploinsufficiency
or negative dominance?
In this issue of Immunity, Oftedal et al.
(2015) report multiple dominant-negative
mutations of AIRE underlying AD APS1.
These data suggest that mutations in
AIRE might be more widespread in pa-
tients with autoimmunity than previously
thought. A first hint for this idea was pro-
vided by a multiplex family with autoim-
munity segregating with a missense het-
erozygous AIRE mutation in the SAND
domain (Cetani et al., 2001), the disease-
causing role of which was confirmed in a
mouse knock-in model (Su et al., 2008).
Here, Oftedal et al. (2015) describe multi-
ple familial and sporadic instances of
autoimmunity associated with rare vari-
ants of AIRE that cluster in its PHD1
domain (Figure 1). One multiplex pedi-
gree, in particular, provided a strong
genetic case for AD inheritance. An
APS1 patient with a single heterozygous
AIRE mutation in the PHD1 domain had
two separate partners whose children
harbored the heterozygous AIRE muta-
tion and developed APS1. The authors
then identified other patients with APS1-
like features who harbored heterozygous
PHD1 mutations. Screening larger co-
horts of patients with vitiligo or pernicious
anemia also identified patients carrying
heterozygous PHD1 mutations. Finally,
scanning public databases revealed that
PHD1 mutations, some of which might
be dominant negative, reach an estimated
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Figure 1. Model of Autosomal-Dominant APS1
Missense or other in-frame mutations in the PHD1 domain of AIRE can confer dominant interference of
AIRE function. AIRE is known to form self-multimers through the HSR/CARD domain. Shown at the top
left are the major domains of AIRE. Normally, two wild-type copies of AIRE are present and their products
multimerize for normal AIRE function. Individuals with two wild-type copies of AIRE are normally healthy
with no clinical autoimmunity (left). Oftedal et al. (2015) identified mutations in the PHD1 domain of AIRE
that result in the formation of multimers containing mutant (red) and wild-type PHD1 AIRE molecules. The
consequence of these multimers appears to be dominant interference of AIRE function, which probably
affects tissue-specific self-antigen expression in the thymus, but to what degree this occurs in vivo is
not certain. The qualitative and quantitative impact of this interference predisposes to the specific auto-
immune features of AD APS1. Individuals with bi-allelic mutations in AIRE, in the HSR/CARD domain for
example, have a complete loss of AIRE function (right) resulting in classical AR APS1 that presents with
multiple clinical features of early onset and severe outcome. The ultimate manifestation of autoimmunity
in a given individual is on a spectrum, with AD APS1 frequently manifesting with fewer features and later
onset than AR APS1. Furthermore, patients who present with isolated features of APS1 like vitiligo and
pernicious anemia might have heterozygous mutations in AIRE as their underlying genetic predisposition
to disease (left end of spectrum).
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Previewsfrequency of about 0.0008, which is in
the range of several autoimmune condi-
tions that affect about 1 in 1,000 people.
When compared with patients bearing
bi-allelic mutations in AIRE and showing
the classic AR APS1 phenotype, patients
carrying mono-allelic dominant-negative
mutations typically show a narrower,
organ-specific phenotype of later onset
and better outcome—the novel AD APS1
phenotype. Patients with isolated features
of APS1 like vitiligo or pernicious anemia
might harbor a single, rare, dominant-
negative variant in AIRE.
Many questions arise from these pro-
vocative findings. First, what molecular
insights can be garnered? Among the
multiple domains of AIRE, the CARD/
HSR domain is involved in self-multimeri-
zation and the PHD1 domain is a histone
code reader that binds to H3 histone tails
with the K4me0 mark. Thus, in-frame mu-
tations in only one PHD1 domain might
inhibit the function of an entire AIREmulti-
mer. How much negative dominance isgoing on in vivo with PHD1 mutations? Is
there preferential interference for some
but not all transcriptional targets of
AIRE? Currently, this is difficult to ascer-
tain because of the limitations in assess-
ing AIRE function with the in vitro cell
transfection model that was deployed in
the current study. In a previous study of
a mouse knock-in model of a dominant-
negative AIRE SAND mutation, global
interference of AIRE targets in vivo was
observed (Su et al., 2008). Interference
of the PHD1 domain could have a different
effect. Another interesting question is why
such mutations in the PHD1 domain had
been previously missed. Autoimmunity
was perhaps not finely studied in hetero-
zygous relatives of APS1 subjects with
PHD1mutations. Also, some PHD1muta-
tions might be less or not dominant nega-
tive, or perhaps the current study has
enrichment for unique cohorts and pa-
tients. Indeed, pernicious anemia and
vitiligo are more common autoimmune
diseases than APS1 but are seen inImmunityAPS1. Heterozygous AIRE mutations
might therefore contribute to specific
autoimmune conditions, which had not
been previously mined for rare mutations.
Finally, could haploinsufficiency at the hu-
man AIRE locus also predispose to even
milder forms of autoimmunity, as sug-
gested by one of the two mouse models
that examined this question (Liston et al.,
2004; Su et al., 2008)?
What does this study tell us about the
genetic architecture of autoimmunity? In
patients with AD APS1, there is a causal
relationship between genotype and
phenotype, with an immunological mech-
anism and therefore clinical implications.
Variants of similarly low frequency in other
genes might also drive autoimmunity in
other patients. AD forms of autoimmunity
are likely to exceed AR forms. The three
types of AD inheritance might operate,
as recently illustrated by haploinsuffi-
ciency at the CTLA4 locus (Kuehn et al.,
2014) and gain-of-function at the IFIH1 lo-
cus (Rice et al., 2014). This novel genetic
architecture of autoimmunity based on
rare variants, monogenic drivers, and ge-
netic heterogeneity contrasts point by
point with the traditional model of com-
mon variants, polygenic inheritance, and
genetic homogeneity. GWASs based on
the latter model yielded relative risks
around 2, in the best cases, which were
statistically but neither biologically nor
medically significant. So far, the HLA
associations of the pre-GWAS era have
provided the best results of complex
genetics in the realm of autoimmunity.
For example, HLA-DQ8 and HLA-B27
are strong determinants of type 1 dia-
betes and ankylosing spondylitis, respec-
tively, with relative risks in the range of 30.
Although the penetrance of AD APS1 is
incomplete, the relative risk conferred by
pathogenic AIRE mutations is probably
much higher. To measure both the pene-
trance and relative risk, it will be neces-
sary to sequence AIRE in large cohorts
of healthy individuals and autoimmune
patients and to characterize experimen-
tally in-depth all mutant alleles. When
compared with AIRE mutations, the HLA
alleles can be seen as disease-modifying,
but not disease-causing, alleles. The HLA
alleles of AD APS1 patients might even be
modifiers that influence their autoimmune
phenotype, as suggested by HLA DQ
0602 being protective for type 1 diabetes
in AR APS1 patients.42, June 16, 2015 ª2015 Elsevier Inc. 987
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PreviewsWhy did it take so long for monogenic
forms of autoimmunity to gain recogni-
tion?Mendelian traits have often been ne-
glected because of their supposed rarity,
with the perpetual comparison of com-
plex/common versus Mendelian/rare
diseases. This dates back to the turn of
the 20th century, when biometricians
attacked Mendelism. Because most phe-
notypes do not segregate as Mendelian
traits, it was believed that the core Men-
delian principles of genetics were also
wrong. This controversy is not yet entirely
settled, and the term Mendelian is still
used in two ways, referring to monogenic
traits (not necessarily fully penetrant) or
to fully penetrant traits (not necessarily
monogenic). Moreover, there is obviously
no pure Mendelian trait, both fully mono-
genic and fully penetrant, as there is no
single-gene organism defining a single-
organism population. Even cystic fibrosis
and sickle-cell disease are not, strictly
speaking, Mendelian disorders. There-
fore, although Mendelian disorders might
be individually rare exceptions (albeit
collectively numerous), ‘‘non-Mendelian
monogenic disorders’’ might be much
more common, individually and collec-
tively, and perhaps closer to the rule988 Immunity 42, June 16, 2015 ª2015 Elsevthan exceptions. The present study points
to the importance of such disorders in
autoimmunity. Of course, not all autoim-
mune patients carry monogenic lesions:
autoimmunity could be digenic, with two
loci of equal weight, or perhaps even tri-
genic. It could be somatic too, as illus-
trated by the impact of somatic FAS
mutations (Magerus-Chatinet et al.,
2011). Overall, recent breakthroughs in
monogenic autoimmunity remind us of
the heuristic importance of a key
Darwinian concept, referred to in biology
as population thinking by Ernst Mayr and
in medicine as chemical individuality by
Archibald Garrod: all living organisms
are unique (Casanova et al., 2014). There
are only patients, each being unique—
diseases are words used by default
across patients, pending the discovery
of patient-specific pathogenesis.
REFERENCES
Anderson, M.S., Venanzi, E.S., Klein, L., Chen, Z.,
Berzins, S.P., Turley, S.J., von Boehmer, H., Bron-
son, R., Dierich, A., Benoist, C., and Mathis, D.
(2002). Science 298, 1395–1401.
Casanova, J.L., Conley, M.E., Seligman, S.J., Abel,
L., and Notarangelo, L.D. (2014). J. Exp. Med. 211,
2137–2149.ier Inc.Cetani, F., Barbesino, G., Borsari, S., Pardi, E.,
Cianferotti, L., Pinchera, A., and Marcocci, C.
(2001). J. Clin. Endocrinol. Metab. 86, 4747–4752.
Cheng, M.H., and Anderson, M.S. (2012). Annu.
Rev. Immunol. 30, 393–427.
Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K.,
Niemela, J.E., Avery, D.T., Schickel, J.N., Tran,
D.Q., Stoddard, J., Zhang, Y., et al. (2014). Science
345, 1623–1627.
Liston, A., Gray, D.H., Lesage, S., Fletcher, A.L.,
Wilson, J., Webster, K.E., Scott, H.S., Boyd, R.L.,
Peltonen, L., and Goodnow, C.C. (2004). J. Exp.
Med. 200, 1015–1026.
Magerus-Chatinet, A., Neven, B., Stolzenberg,
M.C., Daussy, C., Arkwright, P.D., Lanzarotti, N.,
Schaffner, C., Cluet-Dennetiere, S., Haerynck, F.,
Michel, G., et al. (2011). J. Clin. Invest. 121,
106–112.
Oftedal, B.E., Hellesen, A., Erichsen, M.M.,
Bratland, E., Vardi, A., Perheentupa, J., Kemp,
E.H., Fiskerstrand, T., Viken, M.K., Weetman,
A.P., et al. (2015). Immunity 42, this issue, 1185–
1196.
Rice, G.I., del Toro Duany, Y., Jenkinson, E.M.,
Forte, G.M., Anderson, B.H., Ariaudo, G., Bader-
Meunier, B., Baildam, E.M., Battini, R., Beresford,
M.W., et al. (2014). Nat. Genet. 46, 503–509.
Su, M.A., Giang, K., Zumer, K., Jiang, H., Oven, I.,
Rinn, J.L., Devoss, J.J., Johannes, K.P., Lu, W.,
Gardner, J., et al. (2008). J. Clin. Invest. 118,
1712–1726.A Death Notice for In-Vitro-Generated
GM-CSF Dendritic Cells?Martin Guilliams1,* and Bernard Malissen2,*
1Laboratory of Immunoregulation, VIB Inflammation Research Center, 9000 Ghent, Belgium
2Centre d’Immunologie de Marseille-Luminy, UM2 Aix Marseille Universite´, INSERM, U1104, CNRS UMR7280, 13288 Marseille, France
*Correspondence: martin.guilliams@irc.ugent.be (M.G.), bernardm@ciml.univ-mrs.fr (B.M.)
http://dx.doi.org/10.1016/j.immuni.2015.05.020
Mouse bonemarrow cells cultured with GM-CSF are often used to generate dendritic cells (DCs); in this issue
of Immunity, Helft et al. (2015) show that this classical method produces heterogeneous populations of
myeloid cells that are only distantly related to macrophages and DCs found in vivo.In mice, dendritic cells (DCs) and mono-
cytes are continually replenished from
common DC precursors (CDPs) and
common monocyte precursors (cMoPs)
that are found in the bone marrow (BM).
In contrast, many macrophages (Macs)
develop from embryonic precursors thatseed body tissues before birth and then
self-maintain throughout adulthood (Varol
et al., 2015). Cells that resemble DCs or
Macs can also develop under steady-
state conditions from Ly6Chi monocytes
and have been called monocyte-derived
DCs and Macs, respectively, a processthat is enhanced under inflammatory con-
ditions (Bain et al., 2014; Tamoutounour
et al., 2013). Recent studies based on
ontogeny and global gene expression
profiles showed that CDP-derived DCs
can be organized into two main subsets
denoted as cDC1s and cDC2s (Guilliams
